No new AIDS-defining events were reported after week 48 in participants with CD4+ T-cell count ≥200 cells/mm<sup>3</sup>.<h4>Conclusions</h4>Cumulative safety findings through the BRIGHTE 240-week interim analysis are consistent with other trials in HTE participants with advanced HIV-1 and comorbid disease. The gene discussed is CD4; the disease is AIDS.